References
- Strand V, Evans C, Gibofsky A. Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidence. Am J Manag Care. 2022 Nov;28(12 Suppl):S217–S226. doi:10.37765/ajmc.2022.89296
- Gibofsky A, Jacobson G, Franklin A, et al. An online survey among US Patients patients with immune-mediated conditions: attitudes about biosimilars. J Manag Care Spec Pharm. 2023;29(4):343–349. doi:10.18553/jmcp.2023.29.4.343
- Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of Adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the Phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77(6):914–921. doi:10.1136/annrheumdis-2017-212245
- García-Beloso N, Altabás-González I, Samartín-Ucha M, et al. Switching between reference Adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review. Br J Clin Pharmacol. 2022 Feb;88(4):1529–1550. doi:10.1111/bcp.15101
- Taylor PC, Gonzalez YS, Clark R, Faccin F, Howell O. Outcomes following adalimumab bio-originator to biosimilar switch-a comparison using real-world patient- and physician-reported data in European Countries. Rheumatol Ther. 2023; Apr; 10(2):433–445. doi:10.1007/s40744-022-00526-w.
- Nabi H, Georgiadis S, Loft AG, et al. Comparative effectiveness of two Adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator Adalimumab: nationwide observational study emulating a randomised clinical trial. Ann Rheum Dis. 2021 Nov;80(11):1400–1409. doi:10.1136/annrheumdis-2021-219951
- Pina Vegas L, Sbidian E, Penso L, Claudepierre P. Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database. Rheumatology (Oxford). 2021 Mar;60(3):1243–1251. doi:10.1093/rheumatology/keaa448
- Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics during pregnancy and breastfeeding among women with rheumatic diseases: safety clinical evidence on the road. Front Pharmacol. 2021;12:621247. doi:10.3389/fphar.2021.621247
- Scott R, Parker H, Mccartney S, Harrow P, Williams D, Giles I. Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancy. Obstet Med. 2022 Jun;15(2):104–107. doi:10.1177/1753495X211028779
- State Laws for biosimilar interchangeability. Cardinal Health. Available from: https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/state-regulations-for-biosimilar.html. Accessed October 10, 2023.
- Smolen JS, Caporali R, Doerner T, et al. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. RMD Open. 2021;7(2):e001637. doi:10.1136/rmdopen-2021-001637